SLC2A1 and cancer: Reducing glycolytic metabolism in cancer cells by inhibiting key enzymes of glycolysis or focusing on the use of the competitive glucose analog 2-DG or the GLUT1 inhibitor BAY-876 is effective in inhibiting cancer cell proliferation, which may be able to support the formation of long-term memory CD8+ T cells [173, 174].